Abstract 254P
Background
Cervical cancer is the fourth most common cancer among women worldwide. In India, cervical cancer ranks second among women and there are estimated 96922 newly diagnosed cervical cancer cases and 60078 deaths. Most women present late to medical care facility due to lack of awareness. The management depends on the stage of the tumour, and includes surgery, chemotherapy and radiation. Prognosis of cervical cancer has improved recently due to novel treatment and screening approaches. Improving the quality of life is one of the most important parameters in the management of cervical cancer. Sexual function which is the principal dimension, is frequently compromised by late effects of the disease, and late treatment toxicities. This single center prospective study is one of the few studies which determine how cervical cancer and its treatment can affect the sexuality.
Methods
In this prospective study, conducted from April 2021 to April 2022, in Rajiv Gandhi Government general Hospital, Chennai, India. Post treatment 98 cervical cancer patients, 98 patients of non-gynaecological cancer and a group of 98 healthy women were recruited. Clinical features and Female Sexual Function Index (consists of desire, arousal, lubrication, orgasm, satisfaction, pain) of 3 balanced groups of women were compared.
Results
Higher rates of lymphedema were reported in cervical cancer group. About 99% of patients reported stopping their sexual activity completely during treatment; time to regular sexual activity was 9 months for the cervical cancer group, and 5 months for non-gynaecologic cancer (P =0.001). Mean vaginal length which was assessed by pelvic examination were 5.8 cm, 9.7 cm and 9.8 cm respectively for the cervical cancer group, non-gynaecologic cancer group and the control group (p=0.04). 6 parameter FSFI questionnaire, revealed worse results in the cervical cancer group (mean score was 18.3), but was statistically insignificant.
Conclusions
Sexual function, an important element for an optimal quality of life should be duly addressed throughout treatment, especially radiation. However statistically insignificant, poor sexual function indices in cervical cancer group in our study necessitates psychological component to be included in the multidisciplinary management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
214P - Versican G3 domain promotes myeloma cell proliferation, migration and invasion via activation of FAK/STAT3 signaling
Presenter: Nidhi Gupta
Session: Poster viewing 03
215P - Prospective observational study to evaluate impact of metabolic tumor volume on baseline 18F FDG PET/CT and molecular markers on tumor response rate in patients with diffuse large B-cell lymphoma
Presenter: Ankur Mudgal
Session: Poster viewing 03
216P - Lenalidomide maintenance after whole brain radiotherapy in relapsed/refractory primary CNS lymphoma
Presenter: Bhausaheb Bagal
Session: Poster viewing 03
217P - Role of copper levels in patients with myelodysplastic syndromes
Presenter: Revanth Boddu
Session: Poster viewing 03
218P - Prognostic role of apoptotic index in acute lymphoblastic leukemia
Presenter: Ramya Ramesh
Session: Poster viewing 03
219TiP - Randomised controlled study to compare efficacy & safety of KRd versus VRd regimens in newly diagnosed multiple myeloma using weekly schedule of generic carfilzomib
Presenter: Jasmine Porwal
Session: Poster viewing 03
233P - Cancer awareness, tobacco use and cessation among Malayali tribes, Yelagiri Hills, Tamil Nadu, India: A 8-year follow up study
Presenter: Delfin Lovelina Francis
Session: Poster viewing 03
234P - Epithelial-mesenchymal transition and cancer stem cells: Missing link in oral squamous cell carcinoma
Presenter: Selvaraj Jayaraman
Session: Poster viewing 03
235P - Evaluation of a prognostic model for head and neck cutaneous squamous cell carcinoma using a cumulative number of risk factors
Presenter: Reiichi Doi
Session: Poster viewing 03